Cover Image

Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton's tyrosine kinase inhibitor

Saved in:

Bibliographic Details
Main Authors:	Alison H. Kucharik, MD (Author), Nina B. Curkovic, BS (Author), Julio C. Chavez, MD (Author), Kenneth Y. Tsai, MD, PhD (Author), Andrew S. Brohl, MD (Author), James M. Grichnik, MD, PhD (Author)
Format:	Book
Published:	Elsevier, 2024-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bruton's tyrosine kinase inhibitor associated localized extremity edema and erythema
by: Shannon Meledathu, BS, et al.
Published: (2024)

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review
by: Mitra Rezaei, MD, et al.
Published: (2022)

COMPARING THE INCIDENCE AND RISK FACTORS ASSOCIATED WITH CORONARY ARTERY DISEASE IN PATIENTS RECEIVING BRUTON'S TYROSINE KINASE INHIBITORS
by: Niharika Baviriseaty, MD
Published: (2024)

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
by: Kun Wang, et al.
Published: (2021)

Bruton's Tyrosine Kinase in Neutrophils Is Crucial for Host Defense against Klebsiella pneumoniae
by: Zhe Liu, et al.
Published: (2022)

A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context
by: Nicholas Van Rooij, MD, et al.
Published: (2021)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton's tyrosine kinase (BTK) inhibitor
by: Zhou-Peng Xiao, et al.
Published: (2023)

Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
by: Lucie Čermáková, et al.
Published: (2022)

Structural Complementarity of Bruton's Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases
by: Asim Najmi, et al.
Published: (2023)

A comparison of DNA repair pathways to achieve a site-specific gene modification of the Bruton's tyrosine kinase gene
by: David H. Gray, et al.
Published: (2022)

Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants
by: Holger Scheible, et al.
Published: (2021)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib
by: Ziwen Lu, et al.
Published: (2022)

PENAPISAN VIRTUAL BERBASIS STRUKTUR DARI DATABASE BAHAN ALAM ZINC SEBAGAI INHIBITOR BRUTON TYROSINE KINASE
by: Fauzan Zein Muttaqin, et al.
Published: (2019)

PENAPISAN VIRTUAL BERBASIS STRUKTUR DARI DATABASE BAHAN ALAM ZINC SEBAGAI INHIBITOR BRUTON TYROSINE KINASE
by: Fauzan Zein Muttaqin, et al.
Published: (2019)

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants
by: Sibel Ucpinar, et al.
Published: (2023)

Use of etanercept in management of tyrosine kinase-inhibitor-induced erythema nodosum
by: Erisa Alia, MD, et al.
Published: (2020)

Rivaroxaban in the treatment of livedoid vasculopathy: A long-term retrospective study
by: Sihan Deng, BS, et al.
Published: (2024)

QSAR modelling, molecular docking, molecular dynamic and ADMET prediction of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors
by: Mourad Aloui, et al.
Published: (2024)

A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor
by: Yuta Koike, MD, PhD, et al.
Published: (2017)

Cutaneous collagenous vasculopathy: A rare case report
by: Kinjal Deepak Rambhia, et al.
Published: (2016)

Vitiligo associated with polycaprolactone-based collagen stimulator filler
by: Chun-Hsien Huang, MD, et al.
Published: (2022)

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
by: Heather Zhang, et al.
Published: (2021)

Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis
by: Timothy J. Turner, et al.
Published: (2024)

Maternal serum soluble fms-like tyrosine kinase-1-to-placental growth factor ratio distinguishes growth-restricted from non-growth-restricted small-for-gestational-age fetusesAJOG Global Reports at a Glance
by: Prithi Rajiv, MD, et al.
Published: (2024)

Nivolumab associated vasculopathy: A novel mechanism
by: Adeeb Haroon, MS, et al.
Published: (2022)

Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid
by: William Damsky, MD, PhD, et al.
Published: (2020)

Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management
by: Asli Bilgic, MD, et al.
Published: (2021)

Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis
by: Liyuan Ke, et al.
Published: (2024)

Thrombotic vasculopathy due to polymer coating emboli after an endovascular procedure
by: Roya S. Nazarian, MD, et al.
Published: (2021)

A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis
by: Sang-Doo Lee, MD, et al.
Published: (2022)

Cutaneous collagenous vasculopathy: light and transmission electron microscopy
by: Debora Sarzi Sartori, et al.
Published: (2019)

HZ-A-018, a novel inhibitor of Bruton tyrosine kinase, exerts anti-cancer activity and sensitizes 5-FU in gastric cancer cells
by: Danjing Liu, et al.
Published: (2023)

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
by: Rhodes JM, et al.
Published: (2021)

ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
by: Krishnarup Ghoshdastidar, et al.
Published: (2020)

Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis
by: Ronan Talty, BS, et al.
Published: (2021)

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
by: Abrahim Abduelmula, BScN, et al.
Published: (2022)

Botulinum toxin-A: A novel treatment for livedoid vasculopathy
by: Angela M. Crotty, MD, et al.
Published: (2022)

Ulcerative livedoid vasculopathy responding to clopidogrel
by: Elaine Kunzler, BS, et al.
Published: (2018)

Tyrosine Kinase Inhibitors' Newly Reported Endocrine Side Effect: Pazopanib-Induced Primary Adrenal Insufficiency in a Patient With Metastatic Renal Cell Cancer
by: Ghada Elshimy MD, et al.
Published: (2020)

Postsurgical skin ulcers caused by cytomegalovirus vasculopathy in a renal transplant recipient
by: Shikha Rao, MD, et al.
Published: (2020)